DAT is chronic, degenerative disease, which decrease quality of patientś life.DAT is one of the most frequent type of dementia (Pidrman, Kolibáš).

The most important signs of DAT are:cognitive deficit, behavioral and psychological symptoms of dementia (depression, apatia, incontinentia…) (Spar, Rue, 2003).

We have 34 patients with DAT in our retrospective study, the age:76,6 years(65-92y).

The goal of our study was follow the efficacy and safety of donepezil, rivastigmine and galantamine during titration phase and continuing phase.

The efficacy of the treatment with inhibitors of cholinesterase we assessed with MMSE and Clock test on first day, 3rd, 6th and 12th months and NPI (Neuropsychiatric Inventory test) during titration and continuing phases.

The safety of the treatment we assessed with the test of side effects, the most frequent were agitation, depression, agression and incontinentia.

Statistically we used CHí test(p=0,05) and ANOVA test.

The efficacy and safety of all inhibitors of cholinesterase were comparable,there were no significant differences and they have very good efficacy during one year treatment.

There were no frequent gastrointestinal side effects during the treatment with rivastigmine during titration and continuinf phase and the result were comparable with donepezil and galantamine without significant differences. There were no imprtant cardiovascular side effects during the long-term treatment with inhibitors of cholinesterase.

The efficacy and safety of all inhibitors of cholinesterase were comparable during titration and long-term treatment and without significant differences.